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1 Methods
1.1 Datasets
1.1.1 Ferret data and the hemagglutination inhibition assay
Sera from 35 influenza-naı¨ve ferrets each infected with a single influenza A/H3N2 virus (viruses isolated between
1989 and 2010) were collected 13-20 (typically 14) days post-infection. These sera were tested with the hemaggluti-
nation inhibition (HI) assay against 74 A/H3N2 influenza viruses isolated globally between 1992 and 2011; the full
titration table is given in Table S1 (see additional excel files). The HI assay is based on the ability of the influenza
virus hemagglutinin protein to cause agglutination of red blood cells (RBCs) and of virus-specific antisera to block
this reaction (3). The ferret antisera were tested against a fixed quantity of each influenza virus (standardized to 4
HA units/25 L). Prior to testing, each ferret antiserum was treated to remove non-specific inhibitors, by combining
1 part antiserum with 4 parts receptor destroying enzyme (RDE) (100 units/25L) (Seiken RDE II, Denka Seiken
Co., Ltd.) and incubating at 37C overnight. Five parts 1.6% (w/v) sodium citrate solution (Ajax Finechem Pty
Ltd.) were then added to the RDE-treated serum and incubated for 30 minutes in a 56C water bath to inactivate
the RDE. The treatment of antiserum resulted in a ten-fold dilution. RDE-treated antiserum was then adsorbed
with 5% (v/v) packed turkey RBC in a 10:1 ratio, mixed by inversion and incubated at room temperature for 30
minutes before centrifugation of the RBC pellet at 2000 rpm for 5 minutes followed by removal of the adsorbed
serum supernatant. Serial two-fold dilutions of the treated antisera in CaMg-free Phosphate Buffered Saline (PBS),
pH 7.2 (Sigma-Aldrich), were used to determine the highest dilution of antiserum capable of blocking agglutination
between test influenza viruses and 1% (v/v) turkey RBCs in a 96 well V-bottom Micro Test plate (Greiner Bio-One).
This dilution is called the HI titer, or HI value. The lower detection limit of the titers was 10 (lower dilutions were
not possible due to the dilution factor associated with RDE treatment). High HI values indicate a close antigenic
relationship between virus and antiserum.
To determine the antibody titer of a human serum, the HI assay was executed as above, but with 50 L of the treated
human serum of interest instead of the ferret antiserum. Following each HI assay, viruses were retitrated to verify
that their HA titer was still at 4-8 HA units/25 L. Ferret antisera from the Wuhan 1995 (WU95), Sydney 1997
(SY97), Fujian 2002 (FU02) and Wisconsin 2005 (WI05) antigenic clusters, and their homologous antigens with
known end-point titers, were included in each assay as positive controls. Day 0 sera and PBS samples were tested
in each assay and served as negative controls.
1.1.2 Ha Nam cohort data
Based on provisional serological data from titrations against a single virus, influenza-like illness (ILI) reports and
polymerase chain reaction (PCR) tests, we selected a subset of individuals from the Ha Nam Household Cohort
Study (12), monitoring households in Ha Nam, Viet Nam. This subset included all individuals from six households
that had a high sampling compliancy and a household size of five or larger (n=36). Additionally, we included
individuals that had a PCR-confirmed infection (n=10), a random subset of participants with serological conversion
(n=14, defined as a 4-fold change in HI titer against a representative strain, see Table S2), and a random subset of
control individuals without reported serological change (n=9). In total, 69 individuals were selected, resulting in 324
landscapes (37 of whom have the full 6-year time series from 2007-2012). The 36 individuals from the six selected
households were titrated with the HI assay against 38 viruses (isolated between 1993-2011), while the remaining 33
individuals were titrated against a more extensive set of 40 viruses to enable further study of the back-boost (viruses
isolated between 1968 and 2011), sufficient serum volume permitting; the maximum dilution measured was 640. If
agglutination was still inhibited at this dilution, the entry was listed as having an end-point of 1280, since 1280
represents the next two-fold dilution that would have been measured under our protocol (applicable to 93 out of
11597 titrations). The full titration table is given in Table S3 (see additional excel files).
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Individuals in the cohort were closely monitored for signs of ILI. Upon detection of ILI, a swab was taken for PCR
analysis (typically taken the next day, or within two days if reported over a weekend) and subtyping (12).
During the cohort study period, two A/H3N2 antigenic clusters circulated: first WI05, and later PE09, as indicated
in Table S2. To indicate the viruses that may potentially have caused infection in a year, we highlight all viruses
belonging to the cluster that circulated in the year prior to each sample collection date in our figures. For example,
in samples collected in 2008 this includes all WI05-type viruses, in 2010 it includes all PE09-type viruses, while in
2009 it includes both WI05 and PE09 type viruses, since both clusters circulated that year.
Year Sampling date Cluster(s) circulating Inclusion test strain
2007 12/2007 WI05 -
2008 12/2008 WI05 A/Vietnam/EL140/2008
2009 06/2009 WI05, PE09 A/Vietnam/TX265/2009
2010 04/2010 PE09 A/Vietnam/TX265/2009
2011 07/2011 PE09 A/Vietnam/TX265/2009
2012 05/2012 PE09 A/Vietnam/TX265/2009
Table S2: Cohort year, sampling date, circulating antigenic clusters and representative antigenic strains
used for seroconversion testing (WI05: Wisconsin 2005; PE09: Perth 2009).
In our data analyses, we used reference viruses against which all subjects were titrated and defined seroconversion
as a 4-fold increase in HI titer against A/Vietnam015/EL134/2008 in years with WI05 circulation, and against
A/Perth/16/2009 for PE09 cluster circulation.
None of the 69 subjects had ever received an influenza vaccination. Only subjects that were 5 years old or older
were enrolled into the Ha Nam cohort, but otherwise no age restrictions where imposed. The stem-plot in Table S4
gives the subject ages at the end of the study period (2012):
0 — 7889
1 — 0022223455556779
2 — 0122235677889
3 — 22358
4 — 0223345788999
5 — 000012222235
6 — 38
7 — 13
8 —
9 — 15
Table S4: A stem-and-leaf-plot representing the ages of the individuals of the Ha Nam cohort in 2012.
A stem-and-leaf plot is similar to a histogram in that the length of the rows indicates the number in each
group, and additionally indicates the data within each group. The row 9 — 15, for example, indicates
two individuals: one aged 91, the other 95.
Each subject was informed of the aims, methods, anticipated benefits and potential risks of the study by a native
Vietnamese-speaking member of the research team in a face-to-face meeting. Participants were provided with age
appropriate information sheets in Vietnamese and asked to sign a consent form witnessed by a member of the study
team. All participants provided written informed consent.
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1.1.3 Vaccination studies
Sera of 106 volunteers pre- and post-vaccination with A/Nanchang/933/95 (study performed in 1997) and sera of
128 volunteers pre- and post-vaccination with A/Sydney/5/97 (study performed in 1998) were collected by CSL Ltd.
(Parkville, Australia). Sera were collected between 26 and 33 days after vaccination. The sera were titrated with HI
against 70 A/H3N2 influenza viruses. For some individuals, sufficient sera was available for titrations against only
a subset of these viruses. Where fewer than 20 antigens could be titrated against either the pre or post-vaccination
sample from an individual, this individual was excluded from the antibody landscapes analyses. This applied to 4
individuals in the 1997 cohort and 5 in the 1998 cohort. For this study, the end-point of the titration was always
determined. The full tables of titrations are given in Table S5 for 1997 and Table S6 for 1998 (see additional excel
files).
Both these studies consist of a fairly dichotomous population, with the majority of individuals either in their late
teens to early twenties, or in their sixties to early seventies (Table S7 and Table S8).
1 — 888899999999999999
2 — 0000000001111222222334449
3 — 0
4 — 8
5 —
6 — 001112222233344444445555556677777899999
7 — 000112222333344445
Table S7: A stem-and-leaf-plot representing the ages of the individuals in the 1997 vaccination study.
1 — 888888889999999999999
2 — 000000011111112223344666677788
3 — 12239
4 — 05679
5 —
6 — 12233444556666777888888999
7 — 000000000011112222223333334444555555
Table S8: A stem-and-leaf-plot representing the ages of the individuals in the 1998 vaccination study.
1.1.4 Phylogenetic analysis of used A/H3N2 influenza viruses
A phylogenetic tree of the viruses used in this study is shown in Figure S1. In this figure, the linear evolution of
influenza A/H3N2 is clear, as shown by a spindly and narrow phylogenetic tree. The tree shows a gradual and
consistent accumulation of genetic changes over time. By colour-coding by antigenic cluster, it can also be seen
that the antigenic evolution of influenza A/H3N2 viruses has been progressive and step-wise, with antigenically
similar viruses circulating for a few years before strains with related but novel antigenic characteristics replace
them. For reference, in the HA1 gene alone, 69 out of 346 amino acid positions were changed from the HK68
A/Bilthoven/16190/68 strain until the PE09 vaccine strain A/Victoria/361/2011 (171 nucleotide mutations).
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A/BILTHOVEN/16190/68 
A/BILTHOVEN/21793/72
A/BILTHOVEN/1761/76
A/BILTHOVEN/2271/76
A/NETHERLANDS/233/82(193N)(7+1 REC)
A/NETHERLANDS/620/89
A/NETHERLANDS/823/92
A/NETHERLANDS/179/93
A/WELLINGTON/1/94
A/BRISBANE/22/94
A/VICTORIA/1/93
A/WELLINGTON/25/93
A/WELLINGTON/96/93
A/VICTORIA/9/94
A/BEIJING/32/92
A/JOHANNESBURG/33/94
A/SHANGDONG/9/93
A/NETHERLANDS/178/95(145K)
A/BRISBANE/22/96
A/WELLINGTON/48/96
A/VICTORIA/47/97
A/PERTH/5/97
A/PERTH/9/97
A/TASMANIA/1/97 
A/WUHAN/359/95
A/AUCKLAND/5/96
A/CANBERRA/1/96
A/BANGKOK/1/97
A/CHRISTCHURCH/1/96
A/NANCHANG/933/95
A/NETHERLANDS/301/99
A/CANBERRA/9/97
A/BRISBANE/5/2002
A/SOUTH AUSTRALIA/84/2002
A/SOUTH AUSTRALIA/53/2001
A/SYDNEY/228/2000
A/TOWNSVILLE/2/99
A/CHRISTCHURCH/68/99
A/SYDNEY/5/97
A/PANAMA/2007/99
A/FUJIAN/140/2000
A/VICTORIA/507/98
A/VICTORIA/577/99
A/NETHERLANDS/213/03
A/PHILIPPINES/472/2002(MDCK)
A/AUCKLAND/20/2003
A/FUJIAN/411/2002
A/TOWNSVILLE/36/2003
A/BRISBANE/342/2003
A/TOWNSVILLE/4/2002
A/WYOMING/3/2003
A/WELLINGTON/1/2004
A/PHILIPPINES/472/2002(EGG)
A/VICTORIA/110/2004
A/NEWCALEDONIA/12/2004
A/FUKUOKA/55/2002
A/CALIFORNIA/7/2004
A/SINGAPORE/37/2004
A/VICTORIA/523/2004
A/BRISBANE/3/2005
A/NEW YORK/55/2004
A/BRISBANE/10/2007
A/VICTORIA/500/2009
A/WISCONSIN/67/2005
A/PERTH/27/2007
A/URUGUAY/716/2007
A/VICTORIA/208/2009
A/VICTORIA/8/2010
A/PERTH/16/2009
A/VICTORIA/361/2011
A/HANOI/EL134/2008
A/HANOI/EL135/2008
A/HANOI/EL140/2008
A/HANOI/EL196/2009
A/HANOI/EL201/2009
A/HANOI/EL204/2009
A/HANOI/EL206/2009
A/HANOI/EL442/2010
A/HANOI/EL443/2010
A/HANOI/EL444/2010
A/HANOI/VN053/20100.05
Figure S1: Phylogenetic tree for the nucleotide sequences of the HA gene for the 81 strains used in our
studies. The sequences were aligned with MAFFT, and the full HA gene was analysed. The initial tree
was constructed with PhyML using the GTR+I+ 4 evolutionary model, and topology and branch length
were optimized in GARLI (version 2.0.19) with 5 separate runs each of 20,000 generations. The strain
names are colour-coded by antigenic cluster designation.
7
1.2 Creating and testing antibody landscapes
All analyses were performed using R software for statistical computing, unless otherwise specified (version 3.0.3,
R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org), the code is available from the
authors on request.
1.2.1 Determining the antigenic map
Antigenic cartography positions sera and viruses in a map based on their HI titrations such that distance between
viruses represents their antigenic relationship (2). This methodology, as implemented in the antigenic cartography
software (lisp-implementation), was used to calculate the coordinates of the viruses based on the titrations with ferret
sera from Table S1. The positions of 74 viruses were found by minimizing the mapping error. An “overlay-merge”
was made with the Smith et al. antigenic map (2), which minimizes the squared error of positioning of viruses in
common between the two data sets (9 viruses), to obtain the coordinates of the 7 antigenic cluster prototype viruses
that were in the Smith et al. antigenic map, but not among the viruses titrated for this study (HK68, EN72, VI75,
TX77, BK79, SI87 and BE89). The resulting antigenic map is shown in Figure S2, and the antigenic coordinates
computed for each virus can be found in Table S9 (see additional excel files).
Figure S2: Antigenic map of the overlay-merge of the viruses used in this study, and the antigenic map as
published in Smith et al. (2). Colored circles are viruses used for the human serum titrations, and color-
coded by antigenic cluster (cluster name indicated). Viruses used to coordinate the map in the overlay-
merging and not used further are shown as small black dots, sera were omitted for clarity. HK68: Hong
Kong 1968; EN72: England 1972; VI75: Victoria 1975; TX77: Texas 1977; BK79: Bangkok 1979;
SI87: Sichuan 1987; BE89: Beijing 1989; BE92: Beijing 1992; WU95: Wuhan 1995; SY97: Sydney
1997; FU02: Fujian 2002; CA04: California 2004; WI05: Wisconsin 2005; PE09: Perth 2009.
1.2.2 Titer correlation with antigenic distance
In order to investigate whether antigenic distance is, as for ferrets, related to HI titers in humans, we calculated the
pairwise Spearman rank correlation of the HI titer responses between all virus pairs as a function of their pairwise
antigenic distance (see Figure S3). Correlation coefficients decrease considerably with antigenic distance, from
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around 0.8 to below 0. This result clearly indicates that antigenically similar viruses have correspondingly similar
HI titers, and thus that one can fit a surface through the HI data to create an antibody landscape. Correlations did
not reach one, even for the smallest antigenic distances, likely because of noise introduced through error in the HI
assay and intrinsic differences between antigens not captured by this measurement of their antigenic characteristics.
The negative correlation for large antigenic differences is likely a result of data structure, where young people have
not been alive in certain decades, and are therefore more likely to be exposed to recent influenza viruses, and vice
versa individuals getting less frequent infections in their adult years, yet having large titers against their childhood
viruses.
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Figure S3: The antigenic distance between all possible antigen pairs is plotted against the corresponding
Spearman’s rank correlation coefficient of the corresponding set of HI titers for the two viruses in the
pair, for all human samples. The solid blue line represents a Loess fit through the data (span 0.5), while
the lighter blue regions indicate the 95% confidence interval for the same fit based on 500 bootstrap
repeats, sampling with replacement.
1.2.3 Generating the antibody landscape
To generate the antibody landscape, titers were converted onto a log scale via:
z = log2(
HI titer
10 )
The log-converted HI titer is plotted as the z-value for each virus strain at the corresponding position on the antigenic
map, a higher value corresponds to more antibody (Figure S4).
Each landscape was calculated using locally-weighted multiple linear regression based on the titration values avail-
able for the given serum sample against n antigens. Each position on the antigenic map is therefore associated with
three variables: the x coordinate associated with the position in the antigenic map, xi; the y coordinate associated
with the position in the antigenic map, yi; and the converted HI titer, zi. To determine the landscape value, a separate
regression is performed for each point in the antigenic map.
For a given point pj (with associated antigenic coordinates xj and yj), the predicted landscape height z^j (in log
units) is calculated as follows. First, Euclidean distances are calculated to obtain the antigenic distance, aij , of each
antigen with respect to the point in question, such that:
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Figure S4: The antibody landscape is extended into an additional (3rd) dimension, to represent the log-
transformed HI titer associated with each antigen when titrated against a given serum.
aij =
p
((xj   xi)2 + (yj   yi)2)
where A is a variable that determines the maximum antigenic distance from pj to which titrations made against
viruses will receive a non-zero weighting when calculating the landscape height (such that 2A effectively represents
the bandwidth of the local regression). Multiple linear regression was then applied to characterize the relation
between the measured titers zi and the coordinate variables x and y, such that for each antigen:
zi = cj + xiyij + Ei
where the regression coefficients cj and j , which are different for each location in the antigenic map, due to the
local nature of the regression, were resolved to minimize the weighted sum of squares of the errors (R function lm()
used, with weights for each antigen point as defined.), S, given by:
S =
nP
i=1
wijEi2
Finally, predicted values for pj are calculated as follows:
z^j = cj + xjyjj
Because the HI assay starts at a dilution of 1:10, the minimum detectable antibody titer is 10. To properly model
undetectable titers, we listed them as 5 in the HI assay or -1 on the log scale and such values were allowed to
take any value between -1 and -10 (because the value should be -1, and is limited to aid optimization) when fitting
the model. These estimated values for undetectable titers were calculated by minimizing the overall root-mean-
square error (RMSE) of the model fit, which was optimized using a limited-memory Broyden-Fletcher-Goldfarb-
Shanno algorithm (L-BFGS-B, iterating once from starting conditions of all non-detectable titers equal to -1). When
calculating the RMSE, prediction errors were discounted when the predicted titer was below 0 and the measured titer
was undetectable (in such a situation, we cannot assess the quality of the fit). When the predicted titer was above
0 and the measured titer was undetectable, the measured titer was assumed to have a value of -1 (as is frequently
done for HI data, see e.g. Beyer et al. (27)). As an example, a predicted titer of 2 for a measured titer that was
undetectable would be accorded an error of (2 - (-1)) = 3.
RMSE =
s
1
n
nP
j=1
(z^j   zj)2
where zj is the original titer value, and z^j is the predicted titer after fitting.
For the Ha Nam cohort data, the maximum detectable antibody titer was 640. Where the titer exceeded this value,
and these are listed as 1280, the corresponding HI log titer is 7, and, equivalently to undetectable titers, values
10
were allowed to take any value between 7 and 10 (the highest HI titer normally observed in an HI assay) and
optimized by minimizing the RMSE of the model fit.
By repeating this fitting procedure over a matrix of different antigenic coordinates, a landscape is plotted in three-
dimensional space within the boundaries of the antigenic map. This surface shows higher antibody levels (higher
HI titers) as elevations, and antigenic regions with lower antibody levels form depressions in the landscape (Figure
S5).
log
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Figure S5: The landscape height is calculated for a matrix of antigenic coordinates within convex hull
of the antigenic map, and the corresponding values show the antibody landscape.
1.2.4 Determining the potential for virus exposure
To approximate the likely extent of viruses to which an individual would have been exposed in their lifetime, we
used information about the circulation of A/H3N2 antigenic clusters (see Figure 4 in Smith et al. (2) and Table
S2), summarized in Table S10. To be conservative, individuals were considered exposed to any virus from the
corresponding antigenic cluster if this cluster had circulated during any year from the year of birth to the year of
sample collection.
Antigenic HK68 EN72 VI75 TX77 BK79 SI87 BE89 BE92 WU95 SY97 FU02 CA04 WI05 PE09
cluster
Years
circulating
1968-
1971
1972-
1974
1975-
1976
1975,
1977
1979-
1986,
1988
1986-
1991
1989-
1992
1991-
1996
1993-
1997
1997-
2004
2002-
2005
2005-
2006
2006-
2009
2009-
2012
Table S10: The years of circulation of the antigenic clusters.
1.2.5 Cross-validation
To determine the optimal value for parameterA in the tricubic weighting function of the landscape fit, which governs
the smoothness of the landscape by making each multiple linear regression more global (larger A values) or local
(smallerA values), we used cross-validation. To represent all data sets (which varied in number and antigens against
which serum was titrated), we performed 100 Monte-Carlo cross-validations on a random subset of 10 individuals
from each of the 5 datasets. This subset of the data set was split into 500 training-test sets, with each training set
consisting of a random subset of 75% of the available titrations (75% of the viruses measured for a given serum
11
were retained, without replacement), and the test set comprising all sera and the remaining 25% of the viruses.
The training set was used to construct landscapes, and the predicted values of the landscape for the test set were
compared with the actual HI results. The same 500 training-test set splits were then used to compare the prediction
error for different settings of A. Subsequently, we repeated this procedure with 50% of the data in the training set,
and 50% in the test set, using the same random subset of individuals.
To obtain the overall prediction error, the RMSE was calculated as described above and averaged across all 50
individual landscapes. If, in a given training-test set split, a test virus had fewer than three surrounding training
virus titrations within six antigenic units (the smallest value of A tested) that prediction value was excluded when
calculating the RMSE for all values of A, and if the predicted and measured HI titer were both <10, this value was
excluded when calculating the RMSE.
Based on the results shown in Figure S6 a value for A of 11 was chosen, as this gave good prediction RMSE
values, for both 75%-25% and 50%-50% training-test set splits, when compared to different values of A, and when
compared to landscapes generated from randomized data (see section 1.2.7).
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Figure S6: Root-mean-square error of prediction, with 100 cross-validation runs, for different settings
of A in the weighting function for locally-weighted multiple linear regression, leaving out 25% or 50%
of the data.
In the 75%-25% split in Figure S6, a value of 8 also returned a low prediction RMSE, but is an outlier from the
smooth trend of the other data points. We further investigated this data point and found that this value likely leads to
over-fitting, which would lead to non-generalizable results: in Figure S7, for A of 8, there are many features visible
that cannot be supported by the data (e.g. the SI87 cluster in blue was only represented by 1 titration, but there are
many narrow features in this region that seem spurious), see also 1.2.9.
1.2.6 Estimating HI accuracy
Inherent measurement error in the HI assay is well recognised, for example due to between-laboratory variation. In
our study, all titrations were performed within the same laboratory, and so we were able to use the repeated samples
taken from the same individuals in the Ha Nam cohort to quantify the repeatability of the results. Ideally, this would
be done by measuring the error in repeated HI assay data, but such data was not available on a large scale. A more
conservative estimate of repeatability may be obtained by investigating changes in antibody titers over consecutive
years for individuals in the Ha Nam that were not infected (i.e. the individual did not seroconvert or have PCR-
confirmed infection), assuming that these individuals have an approximately constant titer response.
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Figure S7: A comparison of landscape fits with when the smoothing parameters A was 8 or 11, for an
individual born in 1960 from the Ha Nam cohort.
We investigated the variability in HI titers between pairwise measurements for all samples of an individual who
were not infected in any year (by PCR or seroconversion). Additionally, we removed individuals that had a re-
sponse against any influenza strain of 16-fold or more, as this suggests serological changes, despite not fulfilling the
seroconversion criterion.
Figure S8A shows the distribution of errors (difference in HI titer) between two repeat measurements of the same
antigen, for the full set of pairwise combinations of HI “repeats” from the same individual in two subsequent years.
Over 60% of the repeats show no change in the HI titer.
To further investigate whether the repeatability depends on the value of the titer, we calculated the error as a function
of HI titer (based on the two entries from both titers forming the pair), see Figure S8B. The distribution of pairwise
differences for HI titers of 0 and larger changed little, being distributed around a mode of 1, and was not significantly
greater for greater HI values. When titers fell in the undetectable range (<10, corresponding to a log-value of -1
for this analysis), consistency between pairs of measurements was further improved, with a mode of 0 (where
both measurements display undetectable cross-reactivity). This may be expected given the larger range of potential
reactivity encompassed by an “undetectable” reading. To avoid artificially deflating the reported RMSE, such pairs
of measurements where both titers were undetectable were excluded from the RMSE and MAE calculations in
sections 1.2.5 and 1.2.7.
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Figure S8: Estimates of HI consistency. (A) Proportional distribution of HI error across all “repeats”.
(B) Proportional distribution of HI error across “repeats” subset by the associated measured titer of either
of the pair.
The RMSE for pairwise agreement between each “repeat”(with at least on of the titers is a numeric measurement,
i.e. 10) is 0.90 (95% CI, 0.86 - 0.93). Note that there are very few instances of a pairwise difference of 4, providing
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evidence that the 4 individuals with a change of>4 had indeed most likely undergone a serological change unrelated
to HI inaccuracy.
1.2.7 Estimating landscape accuracy
After parameterizing the model with A = 11, Monte-Carlo cross validation was used to determine the predictive
ability of the model for the different data sets. Again, 100 repeats were performed using randomly generated
75%-25% training-test set splits. In addition, we randomly associated titrations with different viruses in the Ha
Nam cohort study and used these shuffled values to construct landscapes, as a negative control. We subsequently
calculated the root-mean-square error (RMSE) and the mean absolute error (MAE) for the predictions made for the
test viruses in each individual landscape. Table S11 displays the mean of the RMSE values obtained across the
different test-landscapes and its standard error, as well as the median RMSE and median absolute deviation (MAD);
and the mean and standard deviation of the MAE values. If, in a given training-test set split, a test virus had fewer
than three surrounding training virus titrations within six antigenic units, that prediction value was excluded from
calculations. Also, if both the predicted and measured value were <10, this was not taken as an error of 0 but rather
excluded from the analysis, because it would artificially deflate the RMSE value.
Data set mean RMSE (sd) median RMSE (MAD) mean MAE (sd)
Infection: Ha Nam cohort 1.33 (0.42) 1.29 (0.39) 1.14 (0.38)
Pre-vaccination - 1997 study 1.30 (0.45) 1.26 (0.38) 1.11 (0.40)
Post-vaccination - 1997 study 1.33 (0.36) 1.30 (0.33) 1.10 (0.31)
Pre-vaccination - 1998 study 1.28 (0.45) 1.22 (0.38) 1.10 (0.40)
Post-vaccination - 1998 study 1.26 (0.36) 1.22 (0.31) 1.05 (0.31)
Randomized (Ha Nam) 1.96 (0.69) 1.87 (0.65) 1.39 (0.62)
Table S11: Prediction summaries for the different data sets. The root-mean-square-error (RMSE) and
mean absolute error (MAE) were calculate for individual landscapes, and the distribution parameters
(mean and standard deviation (sd), median and median absolute deviation (MAD)) for these results
are displayed. To act as a negative control with which to compare RMSE values, we also calculated
prediction errors when titrations were randomized across the antigens in the Ha Nam cohort (such that
titrations are no longer related to their original antigen).
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Figure S9: (A) Histogram of the prediction error (landscape predicted titer minus measured HI titer),
across all data sets. (B) A series of boxplots showing the distribution of measured titers associated with
predicted titers (zˆ) binned as indicated. The mid-point of each bin of predicted titers is plotted above it
at x=y as a blue dot, whiskers extend to 1.5 times the inter-quartile range from the box.
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The distribution of all errors across the cross-validation runs in the 4 vaccination data sets and the Ha Nam cohort
data set is shown in Figure S9A; if both the measured and predicted HI titer were <10, this error of 0 was excluded.
If, in a given training-test set split, a test virus had fewer than three surrounding training virus titrations within six
antigenic units, that prediction value was also excluded. The RMSE values in Table S11 for each cohort were similar
and each substantially lower than the prediction error when viruses were only randomly associated with antigenic
coordinates, indicating that the landscape does indeed model underlying structure in the dataset, and is not over-
fitting the data. Given that the error of the HI assay is estimated to be around 0.9 (see section 1.2.6), the goodness
of fit of the landscape is reasonable, but not perfect. Examining the distribution of errors associated with different
fitted values (this time re-including titers that were measured to be <10) in Figure S9B, we can see that although
there is error, measured titers distribute evenly around the predicted value at the full range of landscape values found
in this study (the highest landscape peak across all our studies was 7.42).
Figure S10 displays the distribution of RMSE per individual (i.e. across the 100 training-test set repeat predictions).
It shows that individuals are approximately equally well represented by a landscape, and the errors are of a similar
size as when calculated across the data set as a whole (see Table S11).
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Figure S10: Histograms of the root-mean-squared-error (RMSE) of prediction calculated per individual,
for the 4 vaccination data sets, the Ha Nam cohort, and the negative control (Ha Nam cohort shuffled).
Finally, we also wished to investigate whether there were any virus-specific differences, e.g. if some viruses are
consistently under- or over-predicted in the landscape. Figure S11 shows histograms of prediction errors per virus
for the Ha Nam cohort and the vaccine data sets. These figures indeed demonstrate a consistent bias in prediction
accuracy of viruses, for example NL/620/89 is consistently under-predicted in both data sets, and Victoria/361/11 is
consistently predicted to be higher than it was measured. A similar phenomenon has been described previously by
Lessler et al. (5).
This phenomenon of virus-specific differences in reactivity is the source of the relatively larger RMSE errors we
report above, and related to the biological limit of the correlation in section 1.2.2 to 0.8, instead of 1. These
difference may be in part due to inaccuracies in the representation of antigenic differences between viral strains,
and to factors unrelated to antigenic characteristics, such as intrinsic differences between the avidity of antibody
binding. Such intrinsic differences, which may bias conclusions when investigating only a single virus at a time, are
overcome by the antibody landscapes methodology, as a selection of viral strains are used to infer overall antibody
15
reactivity.
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Figure S11: Histograms showing distribution of prediction errors (calculated as predicted HI titer minus
measured HI titer) per virus, calculated across all individuals and repeats. Top: based on the Ha Nam
cohort data. Bottom: based on the vaccine data sets (pre- and post-vaccination landscapes for the 1997
and 1998 cohorts). Titers predicted to be<10 were excluded from the data set when the measured HI titer
was -1, and if a test virus had fewer than three surrounding training virus titrations within six antigenic
units, that prediction value was excluded from calculation, hence some viruses in sparse regions of the
antigenic map have no values associated with them.
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1.2.8 Calculating a summary path
To create a rotation-independent visualization of the three-dimensional landscape, and additionally to facilitate com-
parison of multiple antibody landscapes, we chose to summarize the landscapes by taking a path that passes through
the different antigenic clusters, thus covering the relevant regions of antigenic space. Figure S12 shows the result
generated by fitting a smoothing spline (smoothing parameter 0.1, Matlab R2013, Natick, MA) through the anti-
genic positions of the viruses used in this study, and all viruses except those of the cluster BE89 (an evolutionary
dead-end) that were included in the map by Smith et al. (2).
fitt
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Figure S12: The smoothing spline through the antigenic map data, and the corresponding projections of
the viruses used in our studies onto this path.
When evaluating the summary representations along the path, it should be kept in mind that the axis of this path does
not equal antigenic distance, because the path curves, and therefore two points along the path may be closer or further
than their direct, Euclidean distance calculated from the respective two-dimensional antigenic coordinates.
1.2.9 Bootstrapping the viruses used to generate the landscapes
Antibody landscapes are necessarily an abstraction of the rawHI titers, to enable both visual analysis and comparison
of large amounts of data. The combination of multiple HI measurements may reduce the error associated with a
single HI measurement, and thus increase the accuracy with which antibody levels can be inferred. However, there
is variation in HI titers between viruses that is not captured by the measurements of antigenic similarity we use and
as such, some details are lost when viewing results in an antibody landscape. By using many viruses however, the
presentation of serum antibody reactivity achieved by antibody landscapes is one that is more robust than serological
results considered in isolation.
Figure S13 is an example to demonstrate a visualization of the degree of certainty with which one can interpret the
features of the landscape, here for the individuals from Figure 2 in the manuscript. By sampling with replacement
from the set of viruses, we created 500 bootstrap repeats, and calculated the antibody landscapes for each boot-
strapped data set. The resulting confidence intervals give some indication of the variability that could be expected
from changes in e.g. the selection of antigenically different viruses, and their influence on the landscape shape.
Based on the variability seen in this figure, and also the consistency of the landscape shape of different individuals
over time, we are confident to interpret the global landscape shape when inferring patterns of the “true landscape”,
but more hesitant to look at narrow features - further supporting the choice of value 11 for parameter A in section
17
1.2.5. In particular, the regions of the landscape that are more sparsely sampled (e.g. in the older antigenic clusters)
have less information, and must therefore be more cautiously interpreted.
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Figure S13: The landscapes from Figure 2 of the main manuscript of PCR-confirmed A/H3N2 infected
individuals from the Ha Nam cohort (gray area, solid line) were subjected to bootstrap resampling (500
draws of the viruses, with replacement). As a result of the bootstrapping, confidence intervals of the
landscape shape were obtained and displayed with respect to the landscape shape (grey, increase and
decrease with respect to the previous year shown in red and beige, respectively), and showing the 50%
(dark blue area) and 75% (light blue area) confidence intervals of the landscape shape.
1.2.10 Sensitivity of antibody landscape to number of viruses
Titrations on the scale undertaken in this study are rarely performed, and time-consuming. For the purposes of future
studies, we therefore investigated if and how a more limited set of titrations would affect the calculated antibody
landscapes. Figure S14 shows the landscapes calculated for individuals in the two vaccination studies using either
the initial data set of 70 viruses, and a subset of 20 viruses chosen such that they were the approximately evenly
distributed throughout the original antigenic space (determined with a Kennard-Stone algorithm (28)).
From this comparison, it can be seen that, although the details of the landscape change, these changes are within
the range of uncertainty of the landscape as was illustrated in Figure S13, and the conclusions about the effects and
differences between the two vaccines remain unaffected.
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Figure S14: (A-C) The antibody landscape results for the vaccination studies based on titration against
70 viruses, as shown in the manuscript Figure 3. (D-F) The antibody landscape results for the vaccination
studies when based on a selection of 20 viruses.
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2 Response to infection
2.1 Plots of individual landscapes
Figure S15 shows the antibody landscapes for 2007-2012, where available, for all 69 individuals in the Ha Nam
cohort study, sorted by year of birth (YoB).
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Figure S15: (see above, pages 20 to 24) Antibody landscapes for all individuals in the Ha Nam cohort,
from the original selection of households and individuals selected as PCR-confirmed infection, sero-
conversion or control. The black line represents the landscape height for a given year along the path
(between 2007-2012, per row). The red shading indicates an increase compared to the previous sam-
ple and beige a decrease. The blue-shaded area indicates antigenic clusters that circulated during an
individual’s lifespan until sample collection. The first sample after a PCR-confirmed influenza virus in-
fection is marked with a colored box, and the corresponding colored number gives the days after ILI: red
corresponds to a sample PCR-positive for A/H3N2, orange for A/H1N1, pink for A/H1N1(pdm), green
for influenza B. Samples that were PCR negative for any influenza subtype are indicated with a blue
box. Titrated virus strains are shown in their corresponding positions along the x-axis, symbol radius
is inversely proportional to antigenic distance from the path, symbol color indicates antigenic cluster.
Contemporary viruses likely having caused the infection are indicated with a red horizontal bar. The
landscapes were cropped based on the most limited set of titrations performed for a given individual,
the cropped area is indicated in gray (the gray line indicates the extended landscape in years where there
were available titrations outside the cropped area). Landscapes marked with * were identified as possible
sample swaps (see section 2.2.2).
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2.2 Analyses of infection data
2.2.1 Quantitative measurement of landscape correlation
We noted a large degree of variability between landscapes of different individuals, yet for a given individual, the
landscape shape was largely maintained over time. To quantify the individuality of the antibody landscape shape of
a person, we compared the Pearson correlation of all pairwise antibody landscapes (summary along the path) from
samples from the same individual in different years versus the correlation with landscapes constructed from samples
taken from other individuals in all years. Average within-person correlation was 0.86 0.22 compared to an average
between-person correlation of 0.28  0.21 (t-test, p-value 0.0001). Figure S16A shows the between-individual
correlations in black boxplots, and red dots are superimposed showing the within-individual correlations. Figure
S16B shows this analysis without individuals with PCR-confirmed A/H3N2 infection or seroconversion in any year,
for which it is expected that the landscape would change. For this subset, the mean within-person correlation was
0.89  0.25, the mean between-person correlation was 0.26  0.23 (t-test, p-value 0.0001).
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Figure S16: Boxplots showing the between-person correlation of antibody landscapes in black, and the
within-person correlation of antibody landscapes as red dots (25% and 75% percentiles are the box limits,
the whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile range
from the box). (A) For all individuals for which landscapes were available for more than one year. (B)
For the subset of individuals that had no PCR-confirmed infection or seroconversion in any year.
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2.2.2 Evaluating potential sample swaps
Serum samples were collected, labeled, and transported carefully but inevitably errors occur, which can be difficult,
if not impossible, to trace. Guided by the unusually low within-person correlations for a small number of individuals,
in contrast to the usually high within-person correlations, we identified likely sample swaps based on the appearance
of landscapes (Figure S17, Figure S18, Figure S19 and Figure S20).
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Figure S17: A potential sample swap in 2007 (legend as Figure S15).
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Figure S18: A potential sample swap in 2009 for individuals within the same household (legend as
Figure S15).
To aid interpretation, where landscape series are shown we have switched back all the likely sample swaps shown
above except the individual born in 2002 (Figure S17, since the likely pair of the swap could not be determined), and
these samples are indicated with an asterisk. We also did this switching back of likely sample swaps when defining
and showing seroconverters.
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Figure S19: A potential sample swap in 2009 for individuals within the same household (legend as
Figure S15).
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Figure S20: A potential sample swap in 2009 for individuals within the same household (legend as
Figure S15).
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2.2.3 The extent of cross-reactivity to viruses circulating before birth
To provide an estimate of the typical extent of cross-reactivity of human antibodies, we investigated HI titers present
against viruses from clusters circulating prior to an individual’s birth, as these were most likely a result of cross-
reactivity from antibodies formed against later clusters. However, we needed to control for singular titrations that
recorded some reactivity for a virus (where the true signal is difficult to differentiate from the measurement error),
and avoid changes due to a likely sample swap. Thus, we determined the lowest measured titer over all the samples
from an individual per virus, and calculated how many antigenic clusters prior to the cluster circulating at birth
included a virus that consistently gave measurable titers. Because cross-reactivity cannot be measured if the first
measurable titer is of the first antigenic cluster that the individual was titrated against, we only included individuals
where titrations extended beyond the antigenic range of measured titers, ensuring that the limit of cross-reactivity fell
within the antigenic range of titrations. Additionally, individuals with no detectable titers to the cluster circulating
in the year they were born were excluded, as they were possibly not infected by influenza from that cluster. The
cross-reactivity span for these individuals (n=17) is shown in Table S12. Thus, the cross-reactivity of antibodies
appears limited to a maximum of 2 antigenic clusters.
Number of clusters prior to birth Number of individuals
with detectable cross-reactivity
0 7
1 7
2 3
3 0
Table S12: The number of antigenic clusters relative to the antigenic cluster circulating at birth, for
which antibody levels were consistently measured for an individual, in order to estimate the extent of
antibody cross-reactivity of antibodies that is maintained long-term.
2.2.4 The antibody response in individuals with PCR-confirmed A/H3N2 infection
Figure S21 shows the antibody landscapes for 2007-2012, where available, for the 12 individuals in our study who
reported ILI that was subsequently PCR-confirmed to be an A/H3N2 infection. We noted an antigenically broad
response that commonly extended to even the oldest A/H3N2 viruses, although the breadth was variable and did not
always include the most antigenically distant viruses.
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Figure S21: (see above, pages 28 to 29) Antibody landscapes for all individuals with PCR-confirmed
A/H3N2 infection in the Ha Nam cohort (legend as Figure S15).
2.2.5 The antibody response in seroconverted individuals
In addition to PCR-confirmed cases of infection with A/H3N2 influenza, a number of individuals show marked
landscape changes between years. The landscapes of individuals (n=36) that met the criterion for seroconversion (a
four-fold or greater change in HI titer to the relevant reference virus titrated, see section 1.1.2) are shown in Figure
S22. Some of these individuals were also PCR-positive for an associated symptomatic A/H3N2 infection, and are
included in this analysis, but were also listed separately in Figure S21. However, 26 other individuals showed
seroconversion without PCR-confirmed infection. These individuals did not report ILI, for example because their
symptoms were too minor to consider reporting, due to non-compliancy in reporting, or because these were genuine
asymptomatic infections.
Some individuals had reported ILI, but were PCR-negative for all influenza subtypes tested. This situation could
result from the lack of an adequate swap taken in the right timeframe needed to detect infection for that individual.
It may also have been that an asymptomatic or otherwise unreported A/H3N2 infection occurred at a different time
between sample collections.
Most of the landscapes shown following seroconversion share the features of a broad back-boosting response fol-
lowing infection that can be clearly seen. One exception is the sample taken from an individual born in 1957 in
2008: although a four-fold change in the reference virus titer was present in this case, the majority of titers remain
unchanged or reduced (the landscape shows signs of antibody decay). Conversely, there were two samples that
follow an A/H3N2 PCR-confirmed infection, and both show visible landscape increases, but do not meet the crite-
rion for seroconversion, and are therefore not included in Figure S21. This demonstrates how the classic criterion
of evaluation of serology data of a four-fold change, based on a single virus, can lead to potentially misleading
results.
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Figure S22: Antibody landscapes for all samples meeting the criterion for seroconversion (see section
1.1.2) of the Ha Nam cohort. Legend as Figure S15, except: the black line represents the landscape
height along the path for the year given above each panel - this is the year of the sample from which
seroconversion was detected. The red shading indicates increases, beige decreases, compared to the
sample taken preceding seroconversion.
2.2.6 Antibody response following PCR-confirmed infection with other subtypes
Figure S23 shows the antibody landscapes for 2007-2012, where available, for individuals with any known infection
of types and subtypes other than A/H3N2: PCR-confirmed A/H1N1, A/H1N1(pdm) or B influenza infection. The
first sample after infection and number of days past ILI are indicated.
Examining Figure S23, most landscapes show no evidence of a response following infection with another subtype.
However, the individual born in 1993 following an influenza A/H1N1(pdm) infection in 2011, and the individual
born in 1977, 114 days following an influenza B infection in 2011, do show a change in antibody landscape. The
finding that in many cases there are no changes seen post PCR-confirmed A/H1N1, A/H1N1(pdm) and influenza
B infection is in contrast to the pattern following A/H3N2 PCR-confirmed infection, where changes were always
apparent.
Given that none of the other individuals with PCR-confirmed influenza B, A/H1N1 and A/H1N1(pdm) infection
show changes in antibody levels, and other studies in the same cohort also found an absence of cross-reactivity (29).
Therefore, we would suggest that the individual born in 1993 with an influenza A/H1N1(pdm) infection in 2011, and
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the individual born in 1977, 114 days following an influenza B infection in 2011, may also have been infected with
A/H3N2 between sample collection dates, but were swabbed outside the time-frame necessary to detect the virus
with PCR, or were infected at another date for which ILI symptoms were not reported. As discussed above, there
have been other individuals that clearly seroconverted, yet were associated with PCR-negative results following ILI,
or even in individuals without reported ILI.
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Figure S23: Antibody landscapes for all individuals with a PCR-confirmed influenza A/H1N1(pdm),
A/H1N1 or B virus infection (legend as Figure S15). The first sample after a PCR-confirmed influenza
virus infection is marked with a colored box, and the corresponding colored number gives the days after
ILI: red corresponds to a sample PCR-positive for A/H3N2, orange for A/H1N1, pink for A/H1N1(pdm),
green for influenza B. Samples that were PCR negative for any influenza subtype are indicated with a
blue box.
2.2.7 Longevity of the antibody response: landscapes over time
To examine change in landscapes in relation to the time elapsed since the onset of symptoms, we used the information
on the exact ILI date for individuals with PCR-confirmed A/H3N2 infection. Figure S24 shows the landscapes for
these individuals, where the position of the subplot along the x-axis marks the time elapsed since the onset of ILI
symptoms. Where available, subsequent samples are shown compared to the previous sample on the timeline to
observe how a given landscape later decays over time. Individuals were ordered vertically based on the time elapsed
between the onset of ILI symptoms and the time of sample collection. Note that landscapes from the same individual
may be repeated in subsequent rows - their first sample following infection may be compared to pre-infection in one
row first, then later, their second sample compared to pre-infection in its relevant “days since ILI” position. This
repeated display creates a visualization of the timeline of changes as the time post-ILI increases, and maximizes use
31
of all the samples as there are multiple post-ILI landscapes per individual, corresponding to different numbers of
days post-infection.
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Figure S24: Antibody landscapes are shown based on the time since ILI for individuals with PCR-
confirmed A/H3N2 infection. The antibody landscape in the last time point before infection is shown
on the left, the first panel in each of the right-hand series of landscapes compares the post-infection
sample with the pre-infection landscape. The number of days post-ILI is given in the top left corner,
and individuals were arranged according to the number of days since the ILI. Each subsequent box
compares the next sample taken from that individual to the previous one in the same row, to evaluate
decay since the first post-infection landscape. Individuals are repeated when, for example, the second
sample taken following an infection is compared to the pre-infection landscape in its appropriate position
in the timeline (colors are used to mark the same individual). The black line represents the landscape
height for a given year along the path. The red shading indicates an increase compared to the previous
sample shown to the left in the same row and beige a decrease. Landscapes were cropped based on the
available titrations performed for that time point.
Figure S24 thus indicates how the magnitude and breadth of the response to infection depend on the time that has
elapsed. Although the limited number of samples available for this analysis prohibits any firm conclusions, we
observe several features of the time-decay. First, antibody responses were first detected between 1 and 17 days post-
ILI, which is consistent with previous reports of antibody responses being detected 7 days post-vaccination (22).
Second, initial antibody responses, i.e. landscapes for samples drawn soon after ILI onset, generally appear broader
than the longer-term changes in antibody levels (also consistent with the analysis in Figure S45). Third, there is
little evidence of further decay for samples beyond approximately a year post-infection, in line with the findings by
32
Horsfall et al. (6). Any post-infection landscape changes that are present at this point were typically maintained for
the remainder of the study.
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3 Response to vaccination
3.1 Plots of individual landscapes
The pre- and post-vaccination landscapes for each individual in the 1997 study, shown in Figure S25, can be used to
investigate the response to vaccination with A/Nanchang/933/95.
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Figure S25: (see above, pages 34 to 35) Antibody landscapes for the 102 individuals in the 1997 study,
vaccinated with A/Nanchang/933/95. The black line represents the pre-vaccination landscape height
along the path; the green line represents the post-vaccination height. The green shading indicates an
increase compared to the pre-vaccination sample and beige a decrease. The blue-shaded area indicates
antigenic clusters that circulated during an individual’s lifespan until sample collection. Titrated viruses
are shown in the corresponding positions, where symbol size is scaled down with antigenic distance from
the path. The dashed green line indicates the projection of the A/Nanchang/933/95 antigen location in
the antigenic map on the summary path. The landscapes were ordered by increasing pre-vaccination
antibody landscape levels to the vaccine strain. Note, unlike in the cohort study, each row of landscapes
represents seven different individuals, not the same individual over time.
Figure S26 shows the results for individuals the 1998 study, vaccinated with A/Sydney/5/97.
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
35
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
Position on antigenic summary path
lo
g 2
(H
I t
ite
r
10
)
0
2
4
6
8
Figure S26: (see above, pages 35 to 36) Antibody landscapes for the 123 individuals in the 1998
study, vaccinated with A/Sydney/5/97. Legend as Figure S25, except: the black line represents the pre-
vaccination landscape height along the path; the blue line represents the post-vaccination height. The
dark blue shading indicates an increase compared to the pre-vaccination sample and beige a decrease.
The dashed blue line indicates the projection of the A/Sydney/5/97 antigen location in the antigenic map
on the summary path. The landscapes were ordered by increasing pre-vaccination antibody landscape
levels to the vaccine strain. Note, unlike in the cohort study, each row of landscapes represents seven
different individuals, not the same individual over time.
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3.2 Analyses of vaccination data
3.2.1 Characteristics of the response to vaccination
As with infection, the response to vaccination in individuals showing a large titer increase for the vaccine antigen
was strikingly antigenically broad, see Figure S25 and Figure S26. As in other vaccination studies, the magnitude of
the response was highly variable among different individuals (Figure S27). In some individuals, there is very little
or no change following vaccination, in others a substantial change is apparent.
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Figure S27: Histogram displaying the maximum titer fold-increase (based on HI titers) upon vaccination
against any virus for the two vaccination studies.
The “antigen trapping” hypothesis, where the effective antigenic dose is lowered by binding of antigen by pre-
existing antibodies and memory cells (5, 7, 10, 19-20), predicts a relation between the pre-vaccination antibody
landscape, and the response observed in the antigenic region of the encountered strain. We also see evidence of a
relationship between pre-vaccination titer and the increase in titers for the vaccine antigen upon vaccination: indi-
viduals with higher pre-vaccination titers typically displayed a smaller response to the vaccine (Figure S28).
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Figure S28: The pre-vaccination titer to the vaccine antigen is related to the response after vaccination
(post-vaccination titer minus pre-vaccination titer) to the vaccine antigen, shown for the two vaccination
studies (with jitter added to individual data points) by linear regression (solid line) and 95% confidence
intervals (dotted lines).
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3.2.2 Comparison of the response to infection versus vaccination
It is often presumed that the response to infection is more broad and/or strong than the response to vaccination. Our
data sets were not directly designed to test this hypothesis, and a fair comparison of the antibody response to infection
and vaccination is difficult because only symptomatic individuals were swabbed for PCR testing, and asymptomatic
or mild cases may have gone unreported. Moreover, the vaccines contained a virus from the WU95 or SY97 clusters,
whereas the infected individuals were exposed to viruses from the WI05 and PE09 clusters. Additionally, the precise
virus in the vaccine is known, but although the range of likely infecting viruses can be estimated, the precise infecting
virus is unknown. Finally, the time of sample draw after exposure was similar for all vaccinees (four weeks), but
varied greatly for the infected individuals, where it would often exceed four weeks.
With these caveats in mind we nevertheless proceed to compare the response to vaccination and infection. We
selected individuals with a substantial antibody response: we examined the responses of those individuals in the
vaccination studies that seroconverted (a 4-fold titer change, i.e. 2 HI units, to the vaccine strain), and the
response of individuals infected with A/H3N2 in the Ha Nam cohort study, established by either PCR-confirmation
or seroconversion (change of 2 HI units to the relevant circulating reference strain, see section 1.1.2).
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Figure S29: A comparison of the antibody response to vaccination and infection. For the two vaccina-
tion studies, individuals with a 4-fold change to the administered vaccine strain ( 2 HI units) were
selected, and the maximum response to any virus is given. For the Ha Nam cohort, the analysis was
performed with individuals with a 4-fold change (2 HI units, “seroconverters”), and for the sub-
set of individuals with PCR-confirmed A/H3N2 infection. Note that these analyses give the maximum
response, irrespective of antigenic location of this response.
Figure S29 shows that the distribution of maximum titer responses is skewed towards greater responses for individ-
uals in the Ha Nam cohort following PCR-confirmed infection, as the density for post-titer - pre-titer differences
that are 3 or higher (an 8-fold dilution change in the HI assay) is higher than in the other histograms of Figure S29.
This is consistent with our previous observation that PCR-confirmed infected individuals often showed strong and
broad antibody increases (except for the sample taken one day post-ILI). The three remaining plots all used the
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same criterion to select “seroconverted” individuals, enabling a comparison of the vaccine and infection data sets.
When comparing the plots of seroconverted individuals, it appears that the response to infection generally does not
appear greater than the response to vaccination: the histograms look similar, although the infection landscape would
typically be obtained longer post-exposure than the vaccination landscape.
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3.3 Comparison of the two vaccination studies
3.3.1 Comparison of pre-vaccination antibody levels
The two vaccination studies consisted of two different groups of individuals, and samples were drawn one year apart
(one study from 1997, the study from 1998). Thus, it was important to check for any difference in levels of pre-
existing antibody prior to comparison of the responses to the two different vaccines. Figure S30 shows the difference
between the mean pre-vaccination landscape heights of each study. In the region between the two vaccines (dashed
lines), the pre-vaccination levels are very similar, and in the rest of the antigenic map the individuals in the 1998
(A/Sydney/5/97) study had minimally increased pre-vaccination landscape. The 95% and 99% confidence intervals
of a t-test comparing the two different pre-vaccination landscape sets are also shown.
Given that higher pre-vaccination titers typically correspond to lower responses ((27), see also Figure S28 above),
if there were any result from this small bias, it would be that the 1998 study, vaccinated with A/Sydney/5/97, should
show a smaller response to vaccination, which is the opposite to what we observed. Thus, the increased response to
A/Sydney/5/97 is unlikely to be an artifact of different pre-vaccination antibody levels.
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Figure S30: The black line represents the difference between the average pre-vaccination landscapes, for
the 1997 (A/Nanchang/933/95) and 1998 (A/Sydney/5/97) studies. The 95% (dark gray) and 99% (light
gray) confidence intervals of a t-test comparing the individuals in the two groups are shown.
To confirm that the pre-vaccination landscapes were indeed comparable, Figure S31 shows the HI values for each
virus when compared with a two-tailed t-test.
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Figure S31: Comparison of the difference in HI titers between 1997 (A/Nanchang/933/95) and 1998
(A/Sydney/5/97) studies. The difference between the sample means of the 1998 and 1997 studies is
shown as a point, colored by antigenic cluster. The bars indicate the 95% confidence interval of a two-
tailed t-test for each antigen.
3.3.2 Comparison of antibody responses to the two vaccines
The comparison of the response to the two vaccination studies (Figure 3C, main manuscript) uses paired pre- and
post-vaccination data: for each individual, the response to vaccination was calculated as post-vaccination minus
pre-vaccination titer. Subsequently, the mean of these responses are compared for the two vaccination studies,
by showing the difference between these two means: a positive titer difference indicates greater benefit from the
A/Sydney/5/97 vaccination and negative indicates a greater benefit from the A/Nanchang/933/95 vaccination. The
associated confidence intervals were based on t-tests comparing the responses of the individuals in the two stud-
ies.
In these calculations, it is difficult to deal with a point in the landscape where the individual had a non-detectable
pre- or post-vaccination titer (<10), because such non-numeric titers are prohibitive for calculating the response (for
a change from <10 to 20, all that can be said is that the response >2-fold). Rather than using a discrete arbitrary
cut-off to select which data points to include when calculating the response, we weighted the values in the t-test
based on pre-vaccination landscape height at each point as follows:
wi =
8<:
1 for zi  0
zi + 1 for  1 < zi < 0
0 for zi < 1
where wi is the weighting for each point and zi is the associated height of the pre-vaccination landscape. Following
this equation, if the pre-vaccination landscape height was  0, the associated vaccination change is weighted 1.
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If the pre-vaccination landscape was  -1, this data point does not contribute to the calculation of the response to
vaccination. Pre-vaccination titers between -1 and 0 are weighted following the linear relationship described.
We also repeated this analysis, by equating a pre-vaccination landscape value  -1 to be -1. The results are shown
in Figure S32, from which the same conclusions about antigenically advancing the vaccine are still drawn. This
approach has the advantage of not biasing the responses measured to those with measurable (and therefore higher)
pre-vaccination titers but necessarily loses power by assuming changes that occur below the sensitivity threshold of
the HI assay are not present. The magnitude of difference in vaccination is therefore lower towards later antigenic
clusters where titers were often below the detectable level and the confidence intervals are artificially narrowed.
Despite these differences between the two methods of analysis, the same phenomena are observed, with an increased
response to A/Sydney/5/97, importantly for the antigenic clusters circulating soon after WU95.
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Figure S32: The average pre-vaccination landscape (black) and landscape after vaccination with (A)
A/Sydney/5/97 (blue) in the 1998 study (123 individuals), or with (B) A/Nanchang/933/95 (green)
in the 1997 study (102 individuals). (C) The average titer increase, i.e. the average difference be-
tween each individual’s post- and pre-vaccination titers, following vaccination with A/Sydney/5/97 and
A/Nanchang/933/95, with 95% (dark gray) and 99% (light gray) t-test based confidence intervals, where
a predicted landscape height of  -1 was treated as -1.
3.3.3 Comparison of the two vaccines across the full landscape
To assess whether the conclusions on antigenically advancing the vaccine held for all antigenic locations of the map,
the difference in vaccination response was examined for each position of the landscape (not only along the summary
path). Figure S33 shows this difference in color-code, and the absence of green regions, and prominent presence of
blue regions clearly indicates that across all regions of antigenic space, responses were either equivalent or greater
following vaccination with A/Sydney/5/97.
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Figure S33: Antigenic map showing the antigenic position of viruses for which titers were determined
in the vaccination studies, represented by dots color-coded by antigenic cluster; the two larger symbols
indicate the two vaccine strains. The shading represents the difference between the mean increase in
landscape height at that antigenic position for individuals vaccinated with A/Sydney/5/97 compared to
those vaccinated with A/Nanchang/933/95 (scale given on right-hand side). Gray represents antigenic
regions outside of the convex hull bounded by the viruses titrated, outside of which the antibody land-
scape would need to be obtained by extrapolation. (A) The result when treating landscape heights of<-1
as -1. (B) The result when weighting the values of landscapes below a detectable level, as described in
section 3.3.2.
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3.3.4 Comparison of the two vaccines based on the HI titers
The results found in the landscapes should also be found when examining differences in titer responses for the two
different vaccines on a per-antigen basis. Figure S34 shows the beneficial effect of antigenically advancing the
vaccine strain, in particular for the SY97 (cyan) and FU02 (yellow) antigenic clusters. As may be expected from the
lack of landscape-based smoothing and no averaging out of measurement errors, the pattern is somewhat variable
between antigens, however, the benefit of vaccination with A/Sydney/5/97 is still evident in the raw data. To correct
for the multiple testing (t-tests were performed for 70 antigens), a Bonferroni correction was used to adjust the 95%
confidence intervals:
Overall confidence level = 1   Individual confidence level = 1  m
where  is 0.05 andm is the number of confidence intervals to be calculated (m = 70).
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Figure S34: Comparison of the increase in HI titers between 1997 (A/Nanchang/933/95) and 1998
(A/Sydney/5/97) studies. The difference between the sample means of the response to vaccination in
the 1998 and 1997 studies (based on the post-vaccination minus pre-vaccination titer for individuals in
both studies) is shown as a point, colored by antigenic cluster. The bars indicate the 95% Bonferroni-
corrected confidence interval of a two-tailed t-test for each antigen.
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3.3.5 Comparison of changes in proportion of subjects with “protective” titers
An alternative approach to compare the responses to the two vaccines is to calculate the number of individuals
with a landscape value corresponding to an HI titer of 40 or higher (which is associated with a 50% protection
rate (30)). Figure S35 shows that the proportion of individuals with titers 40 is comparable pre-vaccination, and
increases upon vaccination, where the proportion with such titers for the SY97 and FU02 clusters is markedly higher
upon vaccination with A/Sydney/5/97. Even when considering only raw titers against the respective vaccine strains,
there was no significant difference in the proportion of individuals with “protective” titers against the WU95 strain
post-vaccination (67% in 1997, 71% in 1998, p-value=0.61) while the difference in proportion against the SY97
vaccine strain was marked (16% in 1997, 39% in 1998, p-value=0.0007). In each case the difference in proportion
of “protected” individuals pre-vaccination was not significant.
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Figure S35: Comparison of the proportion of individuals with a landscape value40 (2 HI units), for the
studies on A/Nanchang/933/95 (green) and A/Sydney/5/97 (blue) in the (A) pre-vaccination landscapes,
and (B) post-vaccination landscapes. Lighter shaded regions represent the estimated standard error of
the proportion protected in each population at each position.
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3.3.6 Analysis of responses to vaccination in elderly
To examine if the beneficial effects of antigenically advancing the vaccine strain are also observed for a group
targeted in seasonal influenza vaccination campaigns, we repeated the analysis on the subset of individuals aged
sixty or over. Figure S36 demonstrates that the findings of the full studies are mirrored when looking at the elderly
only, and that, again, antigenically advancing the vaccine gives similar or improved antibody responses compared to
the A/Nanchang/933/95 vaccine across the full evaluated antigenic range.
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Figure S36: For individuals aged 60 or older, the average pre-vaccination landscape (black) and land-
scape after vaccination with (A) A/Sydney/5/97 (blue) in the 1998 study (62 individuals), or with (B)
A/Nanchang/933/95 (green) in the 1997 study (57 individuals). (C) The average titer increase, i.e.
the weighted average difference between each individual’s post- and pre-vaccination titers, following
vaccination with A/Sydney/5/97 and A/Nanchang/933/95, with 95% (dark gray) and 99% (light gray)
weighted t-test based confidence intervals, where landscape heights of 0 were weighted as described
in section 3.3.2.
3.3.7 Analysis of responses to vaccination in at-risk individuals
Individuals with antibody titers <40 are traditionally considered to be most at risk from influenza infection. Thus, it
was important to determine the antibody response specifically in this group, and to investigate whether the beneficial
effect of antigenically advancing the vaccine strain is also observed for individuals with pre-vaccination titers <40
against A/Nanchang/933/95. Figure S37 demonstrates that this advantage is still observed.
Given that the back-boost appears to be dependent upon prior immunity, we also studied the responses for individuals
with no measurable prior immunity, i.e. a titer <10, to the vaccine strain A/Nanchang/933/95. There were 41
individuals in the 1997 vaccination cohort and 38 individuals in the 1998 vaccination cohort with a<10 titer against
the vaccine strain. Figure S38 shows the results for this subset of individuals (note that it differs from previous
figures, as it also displays the landscape data below a the cutoff of HI titer 10, or 0 on the log-scale).
Although the benefit of the antigenically advanced vaccine is smaller for this subgroup, both groups still have a
similar response against the WU95 cluster, and thus vaccinating with SY97 does not appear to compromise the
response to WU95 even in this group of individuals with <10 pre-vaccination antibody titers. It could be that some
low level of pre-vaccination antibody is still present, e.g. where landscapes are just below 0 on the log-scale, (and
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Figure S37: For individuals with A/Nanchang/933/95 pre-vaccination titers <40, the average pre-
vaccination landscape (black) and landscape after vaccination with (A) A/Sydney/5/97 (blue) in the
1998 study (79 individuals), or with (B) A/Nanchang/933/95 (green) in the 1997 study (77 individuals).
(C) The average titer increase, i.e. the weighted average difference between each individual’s post- and
pre-vaccination titers, following vaccination with A/Sydney/5/97 and A/Nanchang/933/95, with 95%
(dark gray) and 99% (light gray) weighted t-test based confidence intervals, where landscape heights of
 0 were weighted as described in section 3.3.2.
titers can be e.g. 5 instead of 0, but both are measured as <10 in the HI assay). Interestingly, of the 79 individuals
with a <10 HI titer against A/Nanchang/933/95, only 8 in the 1997 and 17 in the 1998 cohort have<10 HI titers for
all of the WU95 viruses. The low, but present, antibodies that react with WU-95 like strains may therefore still lead
to a small back-boost, and a net benefit of the antigenically advanced vaccine in this subgroup in terms of similar
post-vaccination titers against WU95 and improved titers against SY97 with the SY97 vaccine, as compared to the
WU95 vaccine, see Figure S38C.
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Figure S38: For individuals with A/Nanchang/933/95 pre-vaccination titers <10, the average pre-
vaccination landscape (black) and landscape after vaccination with (A) A/Sydney/5/97 (blue) in the
1998 study (38 individuals), or with (B) A/Nanchang/933/95 (green) in the 1997 study (41 individ-
uals). (C) The average titer increase, i.e. the average difference between each individual’s post- and
pre-vaccination titers, following vaccination with A/Sydney/5/97 and A/Nanchang/933/95, with 95%
(dark gray) and 99% (light gray) t-test based confidence intervals, where landscape heights of  -1 were
treated as -1. The gray faded section of the plot in panels A and B represents the landscape below 0, a
region where the landscape becomes somewhat unreliable as it contains more titers that are measured as
<10, and thus the numeric value of the landscape cannot be accurately be inferred (nd: not detectable,
i.e. <10).
3.3.8 Analysis of the 2009-2010 Wisconsin-Perth cluster transition
Using titrations from samples on two other annual seasonal influenza vaccine serology serum panels (samples from
2009 and 2010), we further investigated our findings in the context of another cluster transition (WI05 - PE09).
The full tables of titrations are given in Table S13 for 2009 and Table S14 for 2010 (see additional excel files).
Unlike the period between the 1997 and 1998 vaccination studies, in which the antigenically novel SY97 cluster had
circulated at only very low levels when the 1998 study was done (31), there has been significant circulation of the
PE09-like viruses between the dates of the two studies in 2009 and 2010 (32). This explains the increased levels of
pre-vaccination antibody to PE09-like viruses in the 2010 cohort seen in Figure S39.
For several other reasons, the WU95-SY97 comparison described in the main manuscript is the better surrogate of
evaluating the effect of antigenically advancing the vaccine: (i) the average pre-vaccination titer to the antigenically
advanced SY97 strain was <10 in 1998, whereas as a result of the pre-vaccination antibody-reactivity from PE09
circulation prior to vaccination, the 2010 study less resembles the situation of “pre-emptive” vaccination; (ii) in
the WU95-SY97 study, the pre-vaccination landscapes of the two groups were comparable, which is not the case
for the WI05-PE09 study. This situation highlights the importance of a prospective study, where the two different
vaccination approaches are tried in a clinical study by administering two groups different vaccines at the same time,
to minimize differences in recent and previous exposure histories.
Retrospective examination of the WU95-SY97 and WI05-PE09 cluster transitions evidently show, as did the Ha
Nam infection results, the back-boost stimulated by exposure (Figure S39). When investigating the pre-vaccination
titer for the two different vaccine strains, the titer from the 2009 study against WI05 (dashed blue line) is comparable
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to the titer from the 2010 study against PE09 (dashed purple line). Thus, we would expect similar responses to the
two different vaccines, which is indeed observed, and is in contrast to the response to vaccination observed in the
SY97 group in 1998, where the pre-vaccination titers against the vaccine were lower than the pre-vaccination titers
in the 1997 group against the WU95 strains.
Because antibodies to the PE09 cluster had already appeared by 2010, Figure S39 represents what may be expected
with the current vaccination strategy. From the results of the WU95-SY97 study, we think that if in 2009 the
PE09 vaccine had been used, the overall antibody titers would have been higher. Conversely, we also expect that
administration of WI05 in 2010 would have led to a response that is smaller than that resulting from the PE09
vaccine, because where vaccines lag behind influenza evolution, a loss in effectiveness is recorded. Given the higher
pre-vaccination titers, and the negative relation between pre-vaccination titers and response to vaccination (S28), a
smaller response to the same vaccine can be expected in 2010, than in 2009. Given the lower ability of response
for higher pre-vaccination titers, when we consider the response after correction for the pre-vaccination titer, the
“corrected” response is higher against the PE09 than the WU05 vaccine. However, the difficulties presented when
comparing vaccinations in the context of differing pre-vaccination immunity complicate direct comparison, and
again highlight the need for prospective clinical trials.
Figure S39: Comparison of two different vaccines spanning the WI05 - PE09 cluster transition. (A) The mean
pre-vaccination landscape (gray) and landscape after vaccination with A/Perth/16/2009 (magenta, PE09 cluster) in
the 2009 study (80 individuals), or (B) with A/Brisbane/10/2007 (dark blue, WI05 cluster) in the 2010 study (80
individuals). The 20 titrated virus strains are shown in their corresponding positions along the x-axis. The vertical
dotted lines indicate the position of the WI05 (dark blue) and PE09 (magenta) wild type vaccine viruses. (C) The
average titer increase between each individual’s paired post-vaccination and pre-vaccination titers is shown with
95% (dark gray) and 99% (light gray) t-test based confidence intervals.
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Figure S39: Comparison of two different vaccines spanning the WI05 - PE09 cluster transition. (A) The
mean pre-vaccination landscape (gray) and landscape after vaccination with A/Perth/16/2009 (magenta,
PE09 cluster) in the 2009 study (80 individuals), or (B) with A/Brisbane/10/2007 (dark blue, WI05
cluster) in the 2010 study (80 individuals). The 20 titrated virus strains are shown in their corresponding
positions along the x-axis. The vertical dotted lines indicate the position of the WI05 (dark blue) and
PE09 (magenta) wild type vaccine viruses. (C) The average titer increase between each individual’s
paired post-vaccination and pre-vaccination titers is shown with 95% (dark gray) and 99% (light gray)
t-test based confidence intervals.
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One suggestion for the differences between the responses to two WU95-SY97 vaccines is an intrinsic difference
between the immunogenicity of the two vaccine strains. We deem this unlikely, because differences were antigen-
specific and not present throughout the full antigenic range, and also because similar findings were made for the
WI05-PE09 cluster transition study above. Moreover, Davenport et al. also found that an antigenically different
vaccine may induce a greater response to the antigen of interest than an antigenically matched vaccine: they found
that the A-prime vaccine induced lower antibody levels against A-prime strains than the antigenically unrelated
“swine” vaccine strain (9).
3.3.9 Neutralisation assay results
To check the correspondence between findings made in HI and an alternative neutralisation assay, we performed
virus neutralization tests against both vaccine strains (A/Nanchang/933/95 and A/Sydney/5/97) for pre- and post-
vaccination sera from the 1997 and 1998 vaccination cohorts. Virus neutralization assays were performed by heating
antisera for 30 minutes at 56C. Twofold serial dilutions of the antisera starting at a 1:10 dilution were mixed 1:1
with 100 tissue culture infectious dose50 (TCID50) of the virus stocks. After incubation at 35C for 2h in a 5% CO2
humidified incubator, the antiserum virus mixture was transferred to 96-wells plates containing MDCK cells, which
were washed twice with PBS prior to inoculation. Plates were incubated for 2h at 37C, and inoculum was replaced
by 200 L infection medium. After four days end-point dilutions were read by hemagglutination assay.
Unfortunately, not all samples from the vaccine studies had sufficient volume to enable the virus neutralization
tests, typically sera from high-responders that were previously used for other studies. This led to a sample selection
bias, where there were relatively more low-responders than in the initial cohort, and was particularly present for
the 1998 cohort. We were therefore able to test 80 of 102 sera from the 1997 cohort, and 69 of 123 from the 1998
cohort.
In our analyses, we found that both raw titers and vaccination responses as measured with HI and micro-neutralization
were comparable (see Figure S40), giving an R2 = 0.7698. Overall, it can be seen that virus neutralization titers
tend to be higher than the HI titers.
We then compared the results of HI and neutralization for the pre- and post-vaccination titers per vaccination co-
hort, as shown in Figure S41, and noted that neutralization titers were typically higher, but the relative response
patterns for the different groups remain similar. The mean post-vaccination titers against the WU95 vaccine strain
A/Nanchang/933/95 were similar for the 1997 and 1998 cohort, whether measured by HI or virus neutralization.
Thus, the antigenically advanced vaccine is still not at the detriment of the response to the previous antigenic clus-
ter.
We noted in Figure S40 that a proportion of individuals who had measurable HI titers did not have titers when mea-
sured in the micro-neutralization assay. We therefore also wanted to check whether more of these lower responders
as measured by virus neutralization titers (against WU95 strain A/Nanchang/933/95) were present in the 1998 co-
hort response than the 1997 cohort –because it is important to know if neutralization titers may not find consistently
similar or greater responses to previous clusters with the antigenically advanced vaccine, a key finding to corrobo-
rate. To this end, we performed a proportion test comparing the proportion of subjects in each vaccination cohort
that had a smaller response in the neutralization assay than in the HI assay, against the A/Nanchang/933/95 vaccine
strain. Reassuringly, the proportion of individuals with lower neutralization than HI responses was not statistically
significant being 24% in the 1997 cohort, and 28% in the 1998 cohort (p-value = 0.47).
In summary, the results show good correspondence between titers as measured by HI or micro-neutralization and
give us no reason to doubt the conclusions regarding the benefits of vaccination with an antigenically advanced
virus.
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Figure S40: A regression analysis comparing HI titers with neutralization titers. Left panel: regression
analysis of raw titers, plotting pre- and post-vaccination titers as measured by the two assays. Right
panel: regression analysis comparing the vaccination response (post-vaccination - pre-vaccination titers)
as measured by HI and virus neutralization assay.
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Figure S41: Mean pre- and post-vaccination titers in the subset of the 1997 and 1998 vaccination cohorts
measured using both HI and viral neutralization. Error bars show the standard error based on calculations
of the mean from 500 bootstrap samples from the each dataset with replacement.
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4 Immunological and evolutionary interpretation
4.1 Comparison with “antigenic seniority”
Previous studies have also investigated patterns of influenza antibody reactivity within a population, for example
Lessler et al. , who introduced the concept of “antigenic seniority” (5). Here the authors analyzed neutralization
data from a range of serum samples as part of a cross-sectional study directed at an understanding of the patterns
in the antibody reactivity present in the population against different influenza strains, but not specifically directed at
post-infection responses. They found that in general, the titer to a given strain was lower as the age of the individual
during the circulation of a strain increased. By plotting the pre-vaccination titers for the 1997 and 1998 vaccination
cohorts and the samples taken in 2007 as part of the Hanam cohort in a similar fashion, we were able to compare
our findings with those of Lessler et al. Figure S42 shows the HI titer for each virus compared to the age at the time
of virus isolation for each individual.
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Figure S42: Plot of the 1997 and 1998 pre-vaccination data, and the Ha Nam cohort data in 2007 to
enable comparison with the antigenic seniority study by Lessler et al. The plots show titers (with jitter)
for each individual for each virus, as a function of the age at the time of virus isolation. A loess fit was
applied to the data (span 0.25, R function “loess”) and titers against strains that were isolated only after
the year of sample collection were excluded.
From Figure S42, it is clear that titers isolated before an individual was born decline, as the gap between virus
circulation and birth increases. We additionally calculated the maximum titer for each data set, and found this peaks
at the age of 9.8 years for the 1997 vaccination cohort, 8.2 years for 1998 vaccination cohort and 4.1 years for the
Ha Nam cohort. These are in agreement with the peak found by Lessler et al. at around 7 years of age. The earlier
peak in the Ha Nam cohort may reflect different epidemiological patterns and first infections with influenza at an
earlier age in this population. These data also indicate that the cross-reactivity reaches back by about 10 years on
average, again similar to results by Lessler et al.
Interestingly, in the 1998 vaccination cohort, a second peak is visible around an age of 60 at virus isolation, and
somewhat but not as clearly in the 1997 cohort, whilst is it not at all observed in the Ha Nam cohort. The absence
of the peak in the Ha Nam cohort could be related to the absence of regular vaccination in Vietnam. These findings
may suggest that the uptake of influenza vaccination in the other populations at around this age may be responsible
for higher titers against the strains circulating in these age groups, as a result of seasonal vaccination.
We then examined the peak in each individual’s landscape of these three cohorts in more detail. Rather than simply
taking the average peak of the fit as we did above, we investigated the age of each individual during the circulation
of viruses in the region of the peak landscape titers in Figure S43. The mode of this distribution was at age 3, and
the median was at age 6, corresponding very closely to patterns of influenza exposure in children that have been
reported previously, whereby over 60% of children have experiences their first influenza A/H3N2 infection by the
age of 3 (13).
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Figure S43: Age in individuals across all cohorts in the year of isolation of the influenza virus which
corresponds to the highest region of their antibody landscape.
In general, these results support one interpretation of the term “original antigenic sin”: the statement that a bias is
present in the static amount of antibody towards an increased titer to the first encountered strain. In contrast, as
we have already discussed extensively in the main manuscript, the antibody response to such strains upon influenza
exposure is not biased to these first infection strains. In fact, the phenomenon demonstrated by Lessler et al. and in
Figure S42 may be further evidence for the hypothesis of “antigen trapping”, discussed above in relation to Figure
S28. The antigen trapping mechanism would predict that the first infecting strain has generated more novel anti-
bodies than subsequent exposures, since the first response would occur in the absence of pre-existing antibodies that
have cross-reactivity and could “trap” antigen, and thus lower the amount of antigen available to stimulation a novel
antibody response. Regardless of the underlying mechanisms, the lack of clarity when discussing static, absolute
titers as measured in cross-sectional studies versus antibody responses to infection has created much contradiction
and confusion, in particular in relation to the concept of original antigenic sin to date. We should therefore take care
to separate these concepts clearly in future.
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4.2 Mechanistic understanding of the back-boost
4.2.1 Comparison to primary immune responses
It is well established that a primary immune response to an antigenically variable pathogen produces a cross-reactive
polyclonal antibody response, including even antibodies with heteroclytic properties that show improved binding to
an antigenic variant other than the infecting strain that was used to create the primary response (33). This broad
response is neatly illustrated in antibody landscapes of the first-infection ferret antisera (which were used to generate
the antigenic map), as shown Figure S44. Cross-reactivity, as evaluated in terms of measurable titers (for ferrets
infected with WI05 and PE09 strains), is seen for clusters such as FU02 and CA04, but not for antigenically more
distant clusters such as BE92 and for the PE09-inoculated ferrets WU95.
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Figure S44: Antibody landscapes representing primary ferret responses to exposure to viruses from the
Perth 2009 and Wisconsin 2005 antigenic clusters. The solid black line represents the post-inoculation
landscape while the dashed vertical black line represents the location of the vaccine strain in relation to
the summary path described in section 1.2.8.
Overall, detectable primary infection cross-reactivity in the ferrets tested extended to between 3 and 5 antigenic
clusters before the cluster of the infecting strain. This is greater than the extent of detectable reactivity to clusters
before an individual’s birth as shown in Table S12, but this may be expected since ferret titers were measured at
around the expected peak of the antibody response and it cannot be guaranteed that all of the human subjects would
have even been exposed to the first cluster circulating after they were born. However, even at its peak, the extent of
primary cross-reactivity is eclipsed by that of the back-boost, extending up to the full range of 14 antigenic clusters
in some individuals.
4.2.2 Relationship between antibody response to infection and prior antibody levels
The extent of the response to infection with A/H3N2 was broad, but mostly limited to antigenic clusters that had
detectable antibody levels prior to infection (HI titer 10). In addition to the visualization of this effect in Figure
S21, we quantified the phenomenon in Figure S45, which shows the proportion of individuals with a detectable
response, and the proportion of individuals with detectable pre-exposure antibody levels. Detectable titers were de-
fined as a landscape value>0 (corresponding to HI titer>10), and a detectable response as an increase in landscape
value 0.5 (where any landscape values <0 were treated as 0). Because these proportions decline similarly against
older antigenic clusters, we hypothesize that the extent of the “back-boost” is determined by the extent of detectable
pre-infection antibody reactivity. The same pattern is not observed for the more recent antigenic clusters (e.g. WI05,
PE09), which could be the result of the generation of novel antibodies that are more specific to the infecting virus,
rather than stimulation of prior immunity.
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Figure S45: The proportion of individuals from the Ha Nam cohort with detectable titers prior to either
PCR-confirmed infection with A/H3N2 or seroconversion (red line) is compared to the proportion of
these individuals that show detectable increases in antibody landscapes (blue line).
4.2.3 Evaluation of different mechanistic hypotheses
The mechanism behind the broad back-boost described here is unknown, and the immunological nature of the
response was not investigated as part of this study, however we considered a number of hypotheses and how well
they were supported by the data.
First, we examined whether the extensive breadth of the response witnessed in the back-boost could be the result of
the stimulation of naı¨ve B-cells with extensive cross-reactivity, for example due to binding of the viral antigen to
B-cells responsive to slowly evolving, recycled or highly conserved epitopes. We reasoned that this would predict
responses that are not limited by the extent of pre-existing immunity, which contradicts our observations (see section
4.2.2), for example, we do not see responses against strains that circulated long before an individual’s birth. The
extensive cross-reactivity would instead give responses to any viruses that contain these slowly evolving, recycled,
or highly conserved epitopes, even if they were not previously encountered. In addition, if the response were due to
generation of broadly cross-reactive antibodies, one would expect an equal amount of titer increase across all anti-
gens meaning that, on a log scale, the increase would be larger in regions of lower pre-infection titers (simplistically,
because 10 pre-existing antibodies + 10 new antibodies is a two-fold increase, whereas 1000 pre-existing antibod-
ies + 10 new antibodies is a 1.01-fold increase). However, in the back-boost responses, we observe homogenous
responses (on the log-scale), rather than responses that are smaller (on the log-scale) when the pre-existing titers
were higher. The exponential increases in HI titers across the regions of previously detectable HI titers therefore
seem more indicative of a memory response, whereby memory cells already present are stimulated to undergo clonal
expansion when infection or vaccination occurs.
If the broad back-boost is indeed part of a memory response, we reasoned this could be as a result of either a B-
cell receptor binding independent mechanism, or as part of a response that is broad but nevertheless still requires
some memory B-cell receptor binding affinity. A B-cell receptor binding independent mechanism could arise, for
example, as a result of generalized stimulation of immunological memory cells as a consequence of inflammatory
mediators associated with pathogen exposure. Such a mechanism would result in a broad increase of HI titers against
the wide range of strains, and thus be consistent with the back-boost, and its limitation by pre-existing immunity.
However, this mechanism would not explain the sub-type specific nature of the response. We therefore deem it more
likely that the broad back-boost is the result of broad memory stimulation that requires at least some memory B-cell
receptor binding affinity, i.e. a binding-dependent stimulation of memory cells. Naı¨ve B-cell populations have been
reported to require a higher binding affinity to be stimulated to clonal expansion than existing memory cells, and
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thus are not likely part of the first response of the immune system upon a presenting antigen. Indeed, the broad
back-boost is not at all displaying the characteristic shape that would be expected from a primary immune response,
and that is seen in the ferret HI data that were used to generate the antigenic map. Differences in the binding affinity
of B-cells for the encountered antigen also explain why antibody responses are extensive, but do not always include
the most antigenically distant strains covered by an individual’s immune repertoire.
4.2.4 Original antigenic sin and the back-boost
To characterize the breadth and longevity of the antibody response to infection on the background of prior immunity,
the increase in antibody titer was determined for individuals that had measurable pre-infection titers. Figure S46
shows the titer increases for individuals with PCR-confirmed infection and for seroconverters, where individuals
were excluded from the analysis at the point along the summary path where the predicted titers fell below 0 for
the remaining antigenic region (hence differing sets of individuals along the summary path, and therefore the non-
continuity in the plot). The responses of individuals with PCR-confirmed infection (after ILI, dashed lines) and those
without PCR-confirmation, only seroconverting (dotted lines) are both included and follow a similar pattern.
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Figure S46: For each position along the summary path, the mean increase in titer was calculated based on
a subset of individuals from the Ha Nam cohort that had a detectable titer at that point in the pre-infection
landscape (i.e. pre-infection landscape titer was 10 or higher); based on PCR-confirmed infected indi-
viduals (dashed lines), seroconverters without PCR-confirmation (dotted lines), and the combination of
these two subsets (solid lines). The red lines compare the sample before and immediately after infection,
while the blue lines indicate the titer increase between the last available sample (often from 2012) and
the antibody titers in the year prior to infection (when this was 1 year following the infection).
The initial response to infection (red line) is greater than the long-term increase in titers maintained beyond a year
(blue line); there is a clear overall decay of the initial post-infection response (see also section 2.2.7). In many
individuals this decrease reflects a return to pre-infection titers against older viruses over time, where the greater
increased response to contemporary strains is maintained long-term as an antigenically narrower overall landscape
increase. In some individuals however, increased titers even to the antigenically older regions are somewhat retained
–for this reason, the average long-term responses approach but do not reach 0 in these earlier regions.
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The magnitude of response typically declines as antigenic clusters become more dissimilar to the likely infecting
virus, which in each case would be a virus from either the WI05 (blue) or PE09 (purple) antigenic clusters. Al-
though the response is still substantial to older viruses, responses are largest for more recent viruses –in contrast to
the prediction from the original antigenic sin hypothesis; while the back-boost is different from a typical primary
immune response (see Figure S47).
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Figure S47: For each position along the summary path, the mean increase in titer was calculated based on
a subset of individuals from the Ha Nam cohort that had a detectable titer at that point in the pre-infection
landscape for individuals that were born before 1968, and thus alive during the HK68 pandemic, follow-
ing PCR-confirmed A/H3N2 infection or seroconversion (faint red line). We then represent schematically
the back-boost measured as measured in these responses (red line) and the prediction of titer increase
according to the original antigenic sin hypothesis (blue line) and a typical primary immune response
(green line).
4.2.5 Building-up of antibody landscapes over time
The static appearance of titers being highest against strains that circulated early in an individual’s life has led to
previous hypotheses that such patterns are the result of long-term and progressive reinforcement of antibody titers
against earlier viruses upon exposure to each subsequent antigenic variant over time, see Figure S48A. If the back-
boost were a long-term response, than this would indeed support this mechanism, as it would boost all antigenically
senior strains. However, the back-boost changes over time, and instead we find that although the long-term increase
in the antibody landscape can still span multiple clusters, it is more limited to the antigenic region of the likely
infecting strain (e.g. Figure 2, rightmost column, and Figure S46). This provides evidence against the hypothesis of
long-term and progressive reinforcement of the full breadth of antibody titers, and instead suggests that changes in
serological immunity to strains that are antigenically more distant from the infecting virus are not maintained over
time.
Combining our findings on the nature of the backboost with our findings in support of an “antigen trapping” hy-
pothesis in relation to vaccination, we propose that the lifetime patterns can be alternatively explained by long-term
increases which do not ultimately effect the response to very old strains, but where the strength of the response is
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dependent on antigen trapping. Because the immune response to primary exposure is larger than the responses to
subsequent exposures, due to complete absence of antigen trapping in the first exposure, one would indeed observe
the highest static titers for the antigenic clusters encountered early in life. We do therefore agree with previous sug-
gestions of “immunologic boosting and interference”, since it is similar to the hypothesis that the antigenic trapping
mechanism governs the strength of the long-term response (5). Figure S48B shows a schematic of this alternative
and proposed building-up of the landscape over time, leading to the same static lifetime patterns as explained by
panel A and as observed in previous studies (5, 7-9, 11). Note that there may still initially be a period of “reinforce-
ment” of antibody titers whereby backwards cross-reactivity of antibodies produced against novel but antigenically
similar viruses serves to increase overall serum antibody reactivity towards the first infecting strain - the extent of
this period will depend upon both the rate of antigenic evolution and the degree of cross-reactivity. However, as
antigenic distance increases, this effect ultimately diminishes leaving only transient changes in the titers for the first
infecting strain upon later infections, as we observe in this study.
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Figure S48: Schematic contrasting the building up of landscapes over time by a long-term and progres-
sive reinforcement of all previous antibody titers (panel A), and by more localised responses, where the
strength of the response is dependent on antigen trapping (panel B). Arrows represent the antigenic lo-
cation of the strain involved in each subsequent infection. Shaded regions indicate the end result of each
subsequent infection, as indicated by colors in the legend.
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4.3 Conversion to a protection landscape
We envisage that antibody landscapes will be instrumental in the understanding and prediction of the evolution of
antigenically variable pathogens. For example, the presence of antibodies with cross-reactivity against historical
strains may explain why influenza does not regress, but appears to consistently evolve in antigenic directions that
are consistent with ongoing avoidance of persistent immunological pressures (2, 7). More precise quantification of
the extent of immune escape achieved through antigenic changes will be of paramount importance for studies aiming
to predict the evolution of influenza, as population immunity is a critical part of the pathogen’s fitness.
As an example, we converted the antibody landscape of an individual into a protection landscape based on a quan-
titative relationship between HI titers and clinical protection against influenza (16). The protection landscape in
Figure S49 shows an individual’s protection against the antigenically different influenza viruses. To convert the
landscape, we use the relationship as determined in equation 2 by Coudeville et al. who described the functional
form of relationship between HI titers and protection (the HI protection curve) as follows:
Probability of protection = 1  1
1+e(log(Tj) )
where Tj represents the HI titer and  and  are parameters associated with location and steepness of the HI curve
that they estimate to be 2.844 and 1.299 respectively.
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Figure S49: (A) An example antibody landscape can be converted via (B) the relationship between HI
titer and clinical protection against influenza (16) to (C) a protection landscape, indicating the probability
of protection.
If such a protection landscape can be made to represent the population’s protection, based on HI immunity, against
different influenza viruses, this would quantify a major determinant of viral evolution. Indeed, a population-based
antibody landscape, via the protection landscape, provides a phenotypic landscape, as opposed to most other fitness
landscapes, which are based solely on genotypic or theoretical considerations. Thus, the protection landscape is
an important component of the pathogen’s fitness landscape, where areas of lower population immunity would be
expected to correlate to higher viral fitness and thus a greater likelihood of strain persistence (34, 35).
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